HalcyGen, Hospira deal

HalcyGen will acquire Hospira's Mayne Pharma International Pty. Ltd. subsidiary for US$15 million in cash, plus earn outs over six years. The deal gives HalcyGen full control over SUBA-Itraconazole, which it licensed from Mayne in 2007. HalcyGen plans to submit an MAA for the oral capsule formulation of itraconazole to treat fungal infections in 2010. HalcyGen also gains Mayne's oral drug delivery technologies and manufacturing rights for out-licensed products, including Doryx doxycycline, which is marketed by Warner Chilcott plc (NASDAQ:WCRX, Ardee, Ireland). Hospira gained the subsidiary through its 2007 acquisition of Mayne Pharma Ltd. ...